Amundi’s Dyne Therapeutics DYN Stock Holding History

Amundi’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21	Closed	-$198	–	1810
2025 Q1	$198	Hold	21	–	–	﹤0.01%	2164
2024 Q4	$484	Buy	+21	New	+$621	﹤0.01%	2109

Other funds holding DYN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi's DYN Position: Q2 2025 in Review

Amundi sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 21 shares — an estimated $198 sold.

Amundi first reported a position in DYN in Q4 2024 and held it in 2 quarters. The position peaked at $484 in Q4 2024. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

Amundi reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
Amundi sold 21 Dyne Therapeutics shares in Q2 2025, an estimated $198.
Amundi first reported a position in Dyne Therapeutics in Q4 2024 and held it in 2 quarters.
Amundi's Dyne Therapeutics position peaked at $484 in Q4 2024.
197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.